Meeting
2021 ASCO Annual Meeting
A phase 1 study to evaluate chimeric antigen receptor (CAR) T cells incorporating a chlorotoxin tumor-targeting domain for patients with MMP2+ Recurrent or progressive glioblastoma (NCT04214392).
Presenter
Behnam Badie, MD
City of Hope National Medical Center
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Cellular Immmunotherapy
Clinical Trial Registration Number
NCT04214392
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS2662)
DOI
10.1200/JCO.2021.39.15_suppl.TPS2662
Abstract #
TPS2662
Poster Bd #
Online Only
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2020 ASCO Virtual Scientific Program
A phase I clinical trial on intratumoral and intracavitary administration of ipilimumab and nivolumab in patients with recurrent glioblastoma.
Speaker: Julia Katharina Schwarze, MD
Videos & Slides
2017 ASCO Annual Meeting
Phase I study of AZD1775 with radiation therapy (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM) and evaluation of intratumoral drug distribution (IDD) in patients with recurrent GBM.
Speaker: Brian Michael Alexander, MD, MPH
Videos & Slides
2017 ASCO Annual Meeting
Efficacy analysis of ABT-414 with or without temozolomide (TMZ) in patients (pts) with EGFR-amplified, recurrent glioblastoma (rGBM) from a multicenter, international phase I clinical trial.
Speaker: Andrew B. Lassman, MD
Videos & Slides
2024 ASCO Breakthrough
An exploratory investigator-initiated trial via intrathecal or intracerebroventricular delivery of B7H3-specific allogeneic universal CAR-T cells in patients with recurrent high-grade gliomas.
Speaker: Yulun Huang, MD